Chimeric antigen receptor T cell therapies for multiple myeloma

Multiple myeloma (MM) is the second most common hematologic malignancy and remains incurable despite the advent of numerous new drugs such as proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal antibodies. There is an unmet need to develop novel therapies for refractory/rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chao, Zhang, Lina, Brockman, Qierra R., Zhan, Fenghuang, Chen, Lijuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873434/
https://www.ncbi.nlm.nih.gov/pubmed/31752943
http://dx.doi.org/10.1186/s13045-019-0823-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873434/
https://www.ncbi.nlm.nih.gov/pubmed/31752943
http://dx.doi.org/10.1186/s13045-019-0823-5

Ejemplares similares